SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

August 13, 2012 07:00 ET

Implant Sciences Announces New Sales to Nigeria for Aviation Security

WILMINGTON, MA--(Marketwire - Aug 13, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it continues to gain customers in Nigeria, one of the largest economies in Africa. This latest shipment is to ASL Airlines Services in Lagos, Nigeria. The sale was made through Lagos-based A.C. Belgrave, an in-country distributor for Implant Sciences' products.

ASL Airlines Services is the leading provider of catering and hospitality services to international airlines and airports in Nigeria. The company will use Implant Sciences' QS-H150 explosives trace detectors to execute security search initiatives, including but not limited to screening food and beverage service carts catering to airplanes. ASL Airlines Services caters 700 flight handlings per month for airlines including British Airways, Delta, Lufthansa, Air France and numerous others.

A.C. Belgrave is an established distributor of high quality fire protection and security products with a geographic focus in Nigeria and other countries in Africa. The company is owned and managed by partners with global experience in business and law.

"We are penetrating international markets by working with local distributors like A.C. Belgrave who know their market, have the requisite relationships with decision makers, and are executing on presenting the superiority of our products for designated applications," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "We've been anticipating increased demand for our Quantum Sniffers™ in Nigeria and throughout Africa. This sale affirms we are building traction and we expect this trend to continue."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risk that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2012; that if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; the risk that we continue to incur substantial operating losses and may never be profitable; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact